Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by National Bank of Canada FI

National Bank of Canada FI reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 26.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 93,480 shares of the medical equipment provider's stock after selling 32,889 shares during the quarter. National Bank of Canada FI's holdings in Zimmer Biomet were worth $11,347,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ZBH. Naples Money Management LLC purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $35,000. Activest Wealth Management grew its stake in shares of Zimmer Biomet by 410.4% in the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider's stock worth $42,000 after acquiring an additional 275 shares in the last quarter. Peoples Bank KS bought a new position in shares of Zimmer Biomet during the third quarter valued at about $48,000. Blue Trust Inc. boosted its holdings in Zimmer Biomet by 48.4% during the fourth quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider's stock worth $52,000 after purchasing an additional 153 shares during the last quarter. Finally, Quent Capital LLC grew its position in Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider's stock worth $63,000 after purchasing an additional 92 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Insider Buying and Selling at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the sale, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a filing with the SEC, which is available through this link. 0.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ZBH shares. StockNews.com downgraded Zimmer Biomet from a "strong-buy" rating to a "buy" rating in a research note on Monday, February 19th. Truist Financial decreased their target price on Zimmer Biomet from $137.00 to $130.00 and set a "hold" rating for the company in a research report on Friday, May 3rd. Citigroup boosted their price target on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a "neutral" rating in a report on Wednesday, April 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a "neutral" rating in a research report on Friday, February 9th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $135.40.

Zimmer Biomet Trading Up 0.5 %

Shares of NYSE:ZBH traded up $0.62 on Thursday, reaching $121.47. 667,801 shares of the company traded hands, compared to its average volume of 1,467,514. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $147.50. The company has a current ratio of 1.66, a quick ratio of 0.80 and a debt-to-equity ratio of 0.38. The business's 50-day simple moving average is $125.01 and its 200 day simple moving average is $120.44. The stock has a market capitalization of $24.99 billion, a P/E ratio of 26.29, a price-to-earnings-growth ratio of 2.18 and a beta of 1.03.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, topping analysts' consensus estimates of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The business had revenue of $1.89 billion for the quarter, compared to analysts' expectations of $1.87 billion. During the same period in the previous year, the firm earned $1.89 EPS. The business's quarterly revenue was up 3.2% on a year-over-year basis. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.09 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were paid a $0.24 dividend. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. Zimmer Biomet's payout ratio is presently 20.78%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.